542 related articles for article (PubMed ID: 30702995)
1. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
Ridker PM
Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease.
Ridker PM; Rane M
Circ Res; 2021 May; 128(11):1728-1746. PubMed ID: 33998272
[TBL] [Abstract][Full Text] [Related]
3. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker PM
Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
[TBL] [Abstract][Full Text] [Related]
5. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
Ait-Oufella H; Libby P; Tedgui A
Arterioscler Thromb Vasc Biol; 2019 Aug; 39(8):1510-1519. PubMed ID: 31294625
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Thuren T; Zalewski A; Libby P
Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory therapies for cardiovascular disease.
Ridker PM; Lüscher TF
Eur Heart J; 2014 Jul; 35(27):1782-91. PubMed ID: 24864079
[TBL] [Abstract][Full Text] [Related]
8. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
Grebe A; Hoss F; Latz E
Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500
[TBL] [Abstract][Full Text] [Related]
9. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
Ridker PM
Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
[TBL] [Abstract][Full Text] [Related]
10. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
Ridker PM
J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
[TBL] [Abstract][Full Text] [Related]
12. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
Ridker PM; MacFadyen JG; Thuren T; Libby P
Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
[TBL] [Abstract][Full Text] [Related]
14. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
Ajala ON; Everett BM
Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
[TBL] [Abstract][Full Text] [Related]
16. Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition.
Satish M; Agrawal DK
Transl Res; 2020 Jan; 215():75-85. PubMed ID: 31469975
[TBL] [Abstract][Full Text] [Related]
17. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.
Ridker PM; Howard CP; Walter V; Everett B; Libby P; Hensen J; Thuren T;
Circulation; 2012 Dec; 126(23):2739-48. PubMed ID: 23129601
[TBL] [Abstract][Full Text] [Related]
18. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
[TBL] [Abstract][Full Text] [Related]
19. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.
Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ
Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770
[TBL] [Abstract][Full Text] [Related]
20. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
